mariokartarcadegpdx| HIMS continues to rise by more than 3% before the market and will provide affordable versions of GLP-1 compound drugs

Gelonghui May 21| Yesterday closed up 27mariokartarcadegpdx.66%mariokartarcadegpdxHims & Hers Health(HIMS.US) continued to rise 3.55% to US$19.26 before the market today. The company announced on Monday that it will launch a combination of semigroutide, starting at $199 per month. Novo Nordisk Wegovy, which uses the same ingredients, sells for at least US$1350 per month, and Novotec also costs more than US$900, which means it can be at least 80% cheaper. In the future, an oral weight loss compound drug will also be launched for US$79/month.